Video

Highlights from APCCC 2026

ASCO 2026: Updates in bladder cancer

ASCO 2026: Updates in renal cancer

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups

Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma

Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma

First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma